🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05242055
Recruiting Observational

Integrated Diagnosis and Treatment of CKD on Outcomes

NCT05242055 · tracked via the Priya Life Science China tracker
Sponsor
Capital Medical University
Phase
Observational
Started
2022-02-01
Last updated
2022-05-06

Condition(s) studied

Chronic Kidney DiseasesHypertensionHyperglycemiaHyperlipidemiasAnemiaChronic Kidney Disease-Mineral and Bone DisorderMalnutrition

Investigational drug(s) / intervention(s)

Integrated diagnosis and treatment for CKD

Integrated diagnosis and treatment for CKD: This is an observational study. Investor will not intervene the clinical practice of doctors. In the real world, there would be many factors affect the proceeding of the guidelines contents. There will be integrated diagnosis and treatment during follow-up.

Study summary

Objective: To establish a study cohort and follow up of patients with CKD in our hospital, and evaluate the status of integrated CKD diagnosis and treatment according to guidelines in the real world, as well as the clinical prognosis of patients with different stratification.

Methods: By establishing a cohort of 1000 patients with CKD and conducting long-term follow-up, integrated diagnosis and treatment for CKD was performed, namely: Regular monitoring, control of blood pressure, blood glucose, blood lipid, correction of anemia, minerals - bone metabolic abnormalities, malnutrition, acid and alkali, and electrolyte disorder, diet and exercise, such as the guidance of integrated management, non intrusive, observational studies, prospective cohort were analyzed retrospectively, describe the implementation of the integration of diagnosis and treatment, chronic kidney disease (CKD) Stratified analysis and risk factor analysis were performed for cardiovascular disease and other main endpoint events, so as to objectively reflect the status of integrated treatment of CKD and provide data support for continuous quality improvement of CKD diagnosis and treatment and improvement of clinical prognosis of patients.

Eligibility

Sex
ALL
Min age
18 Years
Max age
100 Years
Healthy volunteers
No
Inclusion Criteria: * ≥18 years old; * Voluntarily signed informed consent; * Patients who are estimated to develop CKD. Exclusion Criteria: * Age \< 18 or ≥100 years; * Unable to comply with the procedures stipulated in this study; * Estimated follow-up time ≤6 months.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Nephrology Department of Beijing Jishuitan Hospital Beijing Beijing Municipality Recruiting

More Capital Medical University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05242055 on ClinicalTrials.gov ↗ ← All trials in China